Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Cadila Pharmaceuticals Limited is a global pharmaceutical company that specializes in the development, manufacturing, and marketing of a wide range of generic drugs and proprietary products. It offers formulations across various therapeutic areas, including cardiovascular, analgesics, and anti-infectives, aimed at improving healthcare outcomes and ensuring access to essential medicines.
Cadila Pharmaceuticals Limited, is an unlisted public company incorporated on 28 February, 1991. It is classified as a public limited company and is located in , Gujarat. It's authorized share capital is INR 120.65 cr and the total paid-up capital is INR 80.01 cr.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Managing Director | Rajiv Indravadan Modi
Shareholder
|
01394558 | 35 years |
| Whole-time Director | Ramesh Ratilal Choksi | 06636737 | 12 years |
| Director | Girdhar Prem Balwani | 00328949 | 0 years |
| Director | Subir Kumar Das | 02237356 | 1 years |
| Director | Rajiv Rajiv Modi | 10276899 | 2 years |
| Director | Parul Nikunj Shah | 09314433 | 2 years |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | 2,082.2 | 2,356.9 | 2,546.2 | 2,522.8 | 2,525.4 |
| Operating profit | 319.4 | 442.2 | 318.9 | 95.4 | 202.4 |
| Net profit | 164.1 | 253.2 | 188.9 | 11.6 | 72.2 |
| Gross margin | 62.5 | 61.3 | 60.1 | 60.5 | 61.1 |
| Operating margin | 15.3 | 18.8 | 12.5 | 3.8 | 8.0 |
| Net margin | 7.8 | 10.7 | 7.3 | 0.5 | 2.8 |
| Networth | 573.5 | 822.5 | 928.2 | 1,431.4 | 1,685.5 |
| Borrowings | 717.8 | 492.0 | 521.9 | 874.6 | 1,219.2 |
| Assets | 1,939.0 | 2,018.2 | 2,275.4 | 3,203.9 | 3,943.9 |
| Debt to equity | 1.2 | 0.6 | 0.6 | 0.6 | 0.7 |
| Current ratio | 1.0 | 1.1 | 1.0 | 1.0 | 1.2 |
| ROE | 28.6 | 30.8 | 20.4 | 0.8 | 4.3 |
| Days payable | 121.0 | 121.0 | 135.0 | 153.0 | 199.0 |
| WC days | 0.0 | 14.0 | -1.0 | -1.0 | 31.0 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 80.0 | 80.0 | 80.0 | 80.0 | 80.0 |
| Reserves | 493.5 | 742.5 | 848.2 | 1,351.4 | 1,605.5 |
| Borrowings + | 717.8 | 492.0 | 521.9 | 874.6 | 1,219.2 |
| Long term borrowings | 420.4 | 305.2 | 256.2 | 533.2 | 844.8 |
| Short term borrowings | 297.4 | 186.8 | 265.7 | 341.4 | 374.4 |
| Trade payables + | 258.9 | 302.8 | 375.1 | 417.3 | 536.6 |
| Days payable | 121.0 | 121.0 | 135.0 | 153.0 | 199.0 |
| Other liabilities + | 647.6 | 703.7 | 825.3 | 897.9 | 1,039.1 |
| Other non-current liabilities | 102.9 | 108.1 | 117.9 | 117.7 | 128.9 |
| Other current liabilities | 285.8 | 292.9 | 332.2 | 362.9 | 373.6 |
| Total liabilities | 1,939.0 | 2,018.2 | 2,275.4 | 3,203.9 | 3,943.9 |
| Fixed Assets + | 724.8 | 727.9 | 721.3 | 1,351.6 | 1,464.8 |
| Tangible assets | 705.8 | 702.2 | 683.5 | 1,224.2 | 1,294.9 |
| CWIP | 11.0 | 16.9 | 30.7 | 120.3 | 157.5 |
| Intangible assets | 8.1 | 8.8 | 7.2 | 7.1 | 12.5 |
| LT loans and advances | - | - | - | - | - |
| Other non-current assets | 369.9 | 417.7 | 586.5 | 739.6 | 978.1 |
| Current assets + | 844.3 | 872.6 | 967.6 | 1,112.8 | 1,500.9 |
| Inventories | 268.3 | 289.3 | 333.7 | 351.0 | 397.3 |
| Trade receivables | 405.9 | 429.0 | 452.5 | 507.8 | 629.8 |
| Cash and cash equivalents | 33.7 | 25.3 | 30.6 | 29.5 | 222.1 |
| ST loans and advances | - | - | - | - | - |
| Other current assets | 136.4 | 129.1 | 150.8 | 224.5 | 251.6 |
| Total assets | 1,939.0 | 2,018.2 | 2,275.4 | 3,203.9 | 3,943.9 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | 2,082.2 | 2,356.9 | 2,546.2 | 2,522.8 | 2,525.4 |
| Sales growth % | 12.81 | 13.19 | 8.03 | -0.92 | 0.1 |
| Expenses + | 1,900.5 | 2,025.8 | 2,327.7 | 2,553.0 | 2,506.1 |
| Cost of goods | 781.8 | 912.7 | 1,016.9 | 996.2 | 983.3 |
| Employee cost | 382.8 | 396.6 | 415.2 | 525.6 | 492.2 |
| Other costs | 598.2 | 605.3 | 795.2 | 905.6 | 847.5 |
| Operating profit + | 319.4 | 442.2 | 318.9 | 95.4 | 202.4 |
| Operating margin % | 15.3 | 18.8 | 12.5 | 3.8 | 8.0 |
| Other income | 25.3 | 14.1 | 41.4 | 53.3 | 39.2 |
| Interest | 75.9 | 47.4 | 35.0 | 60.8 | 111.3 |
| Depreciation | 61.8 | 63.7 | 65.4 | 64.8 | 71.8 |
| Exceptional items | - | - | - | - | 39.7 |
| Profit before tax | 207.0 | 345.1 | 259.9 | 23.1 | 98.1 |
| Tax | 42.9 | 91.9 | 71.0 | 11.5 | 25.9 |
| Profit - disc. ops | - | - | - | - | - |
| Net profit | 164.1 | 253.2 | 188.9 | 11.6 | 72.2 |
| Net margin % | 7.8 | 10.7 | 7.3 | 0.5 | 2.8 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 1.2 | 0.6 | 0.6 | 0.6 | 0.7 |
| Net Debt/Equity | 1.2 | 0.6 | 0.5 | 0.6 | 0.6 |
| Total Debt/Assets | 0.4 | 0.2 | 0.2 | 0.3 | 0.3 |
| Total Assets/Equity | 3.4 | 2.5 | 2.5 | 2.2 | 2.3 |
| Liquidity + | |||||
| Current Ratio | 1.0 | 1.1 | 1.0 | 1.0 | 1.2 |
| Quick Ratio | 0.7 | 0.8 | 0.7 | 0.7 | 0.9 |
| Interest Coverage | 4.2 | 9.3 | 9.1 | 1.6 | 1.8 |
| Performance | |||||
| Gross Margin | 62.5 | 61.3 | 60.1 | 60.5 | 61.1 |
| Operating Margin | 15.3 | 18.8 | 12.5 | 3.8 | 8.0 |
| Net Margin | 7.8 | 10.7 | 7.3 | 0.5 | 2.8 |
| Return + | |||||
| Return on Equity | 28.6 | 30.8 | 20.4 | 0.8 | 4.3 |
| Pre-tax ROCE | 35.4 | 46.3 | 35.4 | 2.3 | 7.8 |
| Return on Assets | 8.5 | 12.6 | 8.3 | 0.4 | 1.8 |
| Pre-tax ROIC | 20.5 | 29.4 | 17.9 | 1.3 | 4.9 |
| Efficiency + | |||||
| Days Payable | 121.0 | 121.0 | 135.0 | 153.0 | 199.0 |
| Days Inventory | 125.0 | 116.0 | 120.0 | 129.0 | 147.0 |
| Days Receivable | 71.0 | 66.0 | 65.0 | 73.0 | 91.0 |
| Fixed Asset Turnover | 2.9 | 3.2 | 3.5 | 1.9 | 1.7 |
| Total Asset Turnover | 1.1 | 1.2 | 1.1 | 0.8 | 0.6 |
| Working Capital | |||||
| Cash Conversion Cycle | 75.0 | 61.0 | 50.0 | 49.0 | 39.0 |
| Working Capital Days | 0.0 | 14.0 | -1.0 | -1.0 | 31.0 |
Axis Trustee Services Limited
No. of Loans: 1
Total Amount : 1,969.3 cr
Bank of Baroda
No. of Loans: 3
Total Amount : 755.0 cr
Canara Bank
No. of Loans: 1
Total Amount : 300.0 cr
Bank of Baroda, CFS Branch
No. of Loans: 1
Total Amount : 300.0 cr
Indian Bank
No. of Loans: 1
Total Amount : 260.0 cr
Bank of Maharashtra
No. of Loans: 1
Total Amount : 216.0 cr
Bank of India
No. of Loans: 2
Total Amount : 200.0 cr
Aditya Birla Finance Limited
No. of Loans: 1
Total Amount : 100.0 cr
Bajaj Finance Limited
No. of Loans: 1
Total Amount : 50.0 cr
RBL Bank Limited
No. of Loans: 1
Total Amount : 4.5 cr
HDFC Bank Limited
No. of Loans: 1
Total Amount : 0.4 cr
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| CPL BIOLOGICALS PRIVATE LIMITED | Gujarat | 2009 | ₹ 45.3 Cr |
| Satellite Overseas (Holdings) Ltd. | Isle Of Man | - | - |
| IRM ENERGY LIMITED | Gujarat | 2015 | ₹ 41.1 Cr |
| Cadila Pharmaceuticals (Ethiopia) Plc. | Ethiopia | - | - |
| SOHL Inc. | United States | - | - |
| Cadila Pharmaceuticals (EA) Ltd. | Kenya | - | - |
| Kadera Yakuhin Ltd. | Japan | - | - |
| Cadila Pharmaceuticals (Europe) Ltd. | United Kingdom | - | - |
| OOO Cadila Pharmaceuticals (Russia) Ltd. | Russian Federation | - | - |
| Modavar Pharmaceutical LLC. | United States | - | - |
| RRM Properties LLC. | United States | - | - |
| Interpharma Industries Ltd. | Nigeria | - | - |
| CPL Biologicals US.LLC | United States | - | - |
| RISM Ltd. | Isle Of Man | - | - |
| Cadila Pharmaceuticals (Uzbekistan) LLC | Uzbekistan | - | - |
| CPL PHARMACEUTICALS PRIVATE LIMITED | Gujarat | 2021 | ₹ 10.0 Cr |
| MARTAND AVIATION GLOBAL HOLDINGS LTD | Ireland | - | - |
| CPL Overseas Trading FZE | United Arab Emirates | - | - |
Read more
The incorporation date of CADILA PHARMACEUTICALS LIMITED is 28 February, 1991
The authorized share capital of CADILA PHARMACEUTICALS LIMITED is INR ₹ 120.7 Cr.
The paid-up capital of CADILA PHARMACEUTICALS LIMITED is INR ₹ 80.0 Cr.
The registered address of CADILA PHARMACEUTICALS LIMITED is CADILA CORPORATE CAMPUS SARKHEJ DHOLKA ROAD,BHAT, AHMEDABAD, Gujarat, India, 382210 - 382210
The CIN number of CADILA PHARMACEUTICALS LIMITED is U24231GJ1991PLC015132.